Sort   by:  
 Page size 
UnknownFinerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.
Not available
S-EPMC9271031 | biostudies-literature
UnknownOutcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.
Not available
S-EPMC10278789 | biostudies-literature
UnknownGlobal, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
Not available
S-EPMC6227755 | biostudies-literature
UnknownConsiderations and consequences of allowing DNA sequence data as types of fungal taxa.
Not available
S-EPMC6048565 | biostudies-literature
UnknownNew-onset atrial fibrillation and chronic coronary syndrome in the CLARIFY registry.
Not available
S-EPMC10834159 | biostudies-literature
UnknownSafety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.
Not available
S-EPMC11249957 | biostudies-literature
UnknownApolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Not available
S-EPMC9422774 | biostudies-literature
UnknownLipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Not available
S-EPMC8822604 | biostudies-literature
UnknownGuidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Not available
S-EPMC4835977 | biostudies-literature
Sort   by:  
 Page size